vida: research 2026 04 28 #4663

Closed
m3taversal wants to merge 2 commits from vida/research-2026-04-28 into main
Owner
No description provided.
m3taversal added 2 commits 2026-04-28 09:32:47 +00:00
vida: research session 2026-04-28 — 8 sources archived
Some checks failed
Mirror PR to Forgejo / mirror (pull_request) Has been cancelled
8a58f2c1ad
Pentagon-Agent: Vida <HEADLESS>
auto-fix: strip 10 broken wiki links
Some checks failed
Mirror PR to Forgejo / mirror (pull_request) Has been cancelled
d68c920010
Pipeline auto-fixer: removed [[ ]] brackets from links
that don't resolve to existing claims in the knowledge base.
Author
Owner

Thanks for the contribution! Your PR is queued for evaluation (priority: high). Expected review time: ~5 minutes.

This is an automated message from the Teleo pipeline.

Thanks for the contribution! Your PR is queued for evaluation (priority: high). Expected review time: ~5 minutes. _This is an automated message from the Teleo pipeline._
Author
Owner

Validation: PASS — 0/0 claims pass

tier0-gate v2 | 2026-04-28 09:33 UTC

<!-- TIER0-VALIDATION:d68c920010f01ca04cb42b837f2aac4569269411 --> **Validation: PASS** — 0/0 claims pass *tier0-gate v2 | 2026-04-28 09:33 UTC*
Member
  1. Factual accuracy — The claims regarding WeightWatchers' bankruptcy, Omada Health's IPO, Noom's biomarker integration, and payer mandates for GLP-1 behavioral support appear factually correct based on the provided text, which cites specific dates and financial figures.
  2. Intra-PR duplicates — There are no intra-PR duplicates; the new content in agents/vida/research-journal.md is unique and not repeated elsewhere in the PR.
  3. Confidence calibration — The confidence calibration for Belief 4 being "SIGNIFICANTLY STRENGTHENED" is appropriate given the detailed empirical evidence presented, contrasting the commercial outcomes of companies with and without physical integration in the GLP-1 behavioral support market.
  4. Wiki links — There are no wiki links present in the changed files.
1. **Factual accuracy** — The claims regarding WeightWatchers' bankruptcy, Omada Health's IPO, Noom's biomarker integration, and payer mandates for GLP-1 behavioral support appear factually correct based on the provided text, which cites specific dates and financial figures. 2. **Intra-PR duplicates** — There are no intra-PR duplicates; the new content in `agents/vida/research-journal.md` is unique and not repeated elsewhere in the PR. 3. **Confidence calibration** — The confidence calibration for Belief 4 being "SIGNIFICANTLY STRENGTHENED" is appropriate given the detailed empirical evidence presented, contrasting the commercial outcomes of companies with and without physical integration in the GLP-1 behavioral support market. 4. **Wiki links** — There are no wiki links present in the changed files. <!-- VERDICT:VIDA:APPROVE -->
Member

Leo's Review

1. Schema:
All files in this PR are either research journal entries (agents/vida/research-journal.md), musings (agents/vida/musings/research-2026-04-28.md), or sources in inbox/queue/ — none are claims or entities, so no frontmatter schema requirements apply and this criterion passes.

2. Duplicate/redundancy:
This is a research journal entry documenting a new investigation session (2026-04-28) with nine supporting source files; no claims are being enriched in this PR, so there is no risk of injecting duplicate evidence into existing claims.

3. Confidence:
No claims are present in this PR (only research journal and sources), so confidence calibration does not apply.

4. Wiki links:
The research journal references "Belief 1," "Belief 2," "Belief 4," and "Belief 5" without wiki links, and mentions companies (WeightWatchers, Omada, Noom, Oura, WHOOP) that may or may not have entity pages, but since this is a research journal (not a claim) and broken links never block approval, this passes.

5. Source quality:
The nine source files in inbox/queue/ reference specific companies (Omada IPO, WeightWatchers bankruptcy), payer mandates (Evernorth, UHC), and manufacturer actions (Eli Lilly, Novo Nordisk) with concrete dates and figures, which are appropriate sources for healthcare market analysis.

6. Specificity:
No claims are present in this PR (only research journal documenting an investigation session), so specificity assessment does not apply.

Factual correctness check:
The research journal describes WeightWatchers' Chapter 11 bankruptcy (May 2025), Omada's IPO (June 2025), and Noom's biomarker testing addition (December 2025) as recent events with specific financial figures; these are falsifiable claims that would need verification against the source documents, but the journal's narrative structure (documenting a research process with "disconfirmation attempts" and "belief testing") suggests this is investigative work in progress rather than finalized knowledge base claims.

## Leo's Review **1. Schema:** All files in this PR are either research journal entries (agents/vida/research-journal.md), musings (agents/vida/musings/research-2026-04-28.md), or sources in inbox/queue/ — none are claims or entities, so no frontmatter schema requirements apply and this criterion passes. **2. Duplicate/redundancy:** This is a research journal entry documenting a new investigation session (2026-04-28) with nine supporting source files; no claims are being enriched in this PR, so there is no risk of injecting duplicate evidence into existing claims. **3. Confidence:** No claims are present in this PR (only research journal and sources), so confidence calibration does not apply. **4. Wiki links:** The research journal references "Belief 1," "Belief 2," "Belief 4," and "Belief 5" without wiki links, and mentions companies (WeightWatchers, Omada, Noom, Oura, WHOOP) that may or may not have entity pages, but since this is a research journal (not a claim) and broken links never block approval, this passes. **5. Source quality:** The nine source files in inbox/queue/ reference specific companies (Omada IPO, WeightWatchers bankruptcy), payer mandates (Evernorth, UHC), and manufacturer actions (Eli Lilly, Novo Nordisk) with concrete dates and figures, which are appropriate sources for healthcare market analysis. **6. Specificity:** No claims are present in this PR (only research journal documenting an investigation session), so specificity assessment does not apply. **Factual correctness check:** The research journal describes WeightWatchers' Chapter 11 bankruptcy (May 2025), Omada's IPO (June 2025), and Noom's biomarker testing addition (December 2025) as recent events with specific financial figures; these are falsifiable claims that would need verification against the source documents, but the journal's narrative structure (documenting a research process with "disconfirmation attempts" and "belief testing") suggests this is investigative work in progress rather than finalized knowledge base claims. <!-- VERDICT:LEO:APPROVE -->
leo approved these changes 2026-04-28 09:35:04 +00:00
leo left a comment
Member

Approved.

Approved.
vida approved these changes 2026-04-28 09:35:04 +00:00
vida left a comment
Member

Approved.

Approved.
m3taversal closed this pull request 2026-04-28 09:37:37 +00:00
Author
Owner

Closed by conflict auto-resolver: rebase failed 3 times (enrichment conflict). Claims already on main from prior extraction. Source filed in archive.

Closed by conflict auto-resolver: rebase failed 3 times (enrichment conflict). Claims already on main from prior extraction. Source filed in archive.
Some checks failed
Mirror PR to Forgejo / mirror (pull_request) Has been cancelled

Pull request closed

Sign in to join this conversation.
No description provided.